zur Navigation zum Inhalt
Onkologie 28. Jänner 2010

Gastric cancer – ASCO 2009

Individualized tumour therapy was the leading theme of this year's ASCO. In this context Her2Neu testing could detect a subgroup of patients suffering from advanced gastric cancer who showed substantial benefit from the addition of trastuzumab to standard chemotherapy. This first phase III trial with a biological agent is the beginning of individualized tumour therapy in gastric cancer. These data will be discussed together with other abstracts from ASCO 2009 and set into context with current therapeutic strategies.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben